Inflammasomes are protein complexes responsible for the release of IL-1 family cytokines, and they play critical roles in immunity and inflammation. The best-characterized inflammasome, the NOD-like receptor protein 3 (NLRP3) inflammasome, is involved in the development of multiple autoimmune diseases. However, the underlying mechanisms of abnormal NLRP3 inflammasome activation in systemic lupus erythematosus (SLE) remain elusive. Here, western blot analysis was used to detect the level of NLRP3 components and mTORC1/2 substrate in the kidney tissues from B6.MRL-FAS lpr /J lupus mice and C57BL/6 mice, and the results showed that mammalian target of rapamycin (mTOR) complex 1/2 (mTORC1/2) and the NLRP3 inflammasome were hyperactivated in B6.MRL-FAS lpr /J lupus mice. The inhibition of mTOR by INK128, a novel mTORC1/2 inhibitor, suppressed LPS/ATP and LPS/nigericin-induced NLRP3 inflammasome activation in bone marrowderived macrophages (BMDMs) in vitro. INK128 decreased both the mRNA and protein levels of NLRP3 in an NF-κB-independent manner. Moreover, we reported for the first time that the inhibition of mTOR suppressed mitochondrial reactive oxygen species (ROS) production in BMDMs stimulated by an NLRP3 agonist. Furthermore, N-acetyl-L-cysteine, a ROS inhibitor, decreased NLRP3 expression, and rotenone, a robust ROS inducer, partially reversed the inhibitory effect of INK128 on NLRP3. These results demonstrated that mTOR regulated the activation of the NLRP3 inflammasome at least partially via ROS-induced NLRP3 expression. Importantly, in vivo data demonstrated that INK128 treatment prominently attenuated lupus nephritis and suppressed NLRP3 inflammasome activation in B6.MRL-FAS lpr /J lupus mice. Taken together, our results suggest that activation of mTOR/ROS/NLRP3 signaling may contribute to the development of SLE.
Introduction
Systemic lupus erythematosus (SLE) is a common autoimmune disease that involves multiple organs and has a variety of clinical manifestations [1] . In SLE, abnormality of innate immune signals may contribute to enduring and refractory inflammation [2, 3] . Nucleotide-binding oligomerization domain-like receptors (NLRs), which are mainly expressed on monocytes/macrophages and can detect microbial components and damage-associated signals, play a pivotal role in inflammation [4, 5] . Recently, the role of NLRs in health and disease has attracted increasing attention [6] .
Among all NLRs, the NOD-like receptor protein 3 (NLRP3) has become the focus of research interests because of its distinctive ability to sense a wide range of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [7, 8] . Activation of NLRP3 inflammasome requires the priming signal (signal 1) and the subsequent activation signal (signal 2). Signal 1 is usually provided by Toll-like receptors (TLRs), and signal 2 is usually provided by various DAMPs and PAMPs. Lipopolysaccharide (LPS), an agonist of TLR4, and ATP, a representative DAMP molecule, are commonly used to activate the NLRP3 inflammasome. Upon activation, NLRP3 interacts with the adapter protein apoptosis-associated speck-like protein, which in turn recruits procaspase-1 to assemble the large protein complex inflammasome, resulting in the autocatalytic activation of caspase-1. Activated caspase-1 can further convert the proforms of IL-1β and IL-18 into bioactive forms [9, 10] . Moreover, NLRP3 may mediate the cross talk between environmental triggers and the development of diseases. An increasing number of studies have indicated the involvement of NLRP3 inflammasome in SLE. Some immune complexes, including dsDNA/anti-dsDNA immune complexes [11, 12] and oxidized low-density lipoprotein immune complexes [13] , have been shown to induce the activation of NLRP3 inflammasome, suggesting that the NLRP3 inflammasome may be triggered in SLE. Moreover, the inhibition of NLRP3 inflammasome could directly attenuate the development of lupus nephritis in MRL/lpr lupus-prone mice [14] . Thus, the activation of NLRP3 inflammasome should be tightly regulated to prevent the development of SLE. However, the molecular mechanisms that control the activation of NLRP3 inflammasome in SLE are still poorly understood.
The mammalian target of rapamycin (mTOR) is a multifunctional serine/threonine kinase that regulates many cellular processes, such as cell metabolism, proliferation, and growth [15, 16] . mTOR is the catalytic subunit of two different protein complexes, mTORC1 and mTORC2, which have distinct kinase activities [17] . It has been reported that the activity of mTORC1 is significantly increased in T cells from SLE patients [18, 19] . Meanwhile, reactive oxygen species (ROS), most of which are produced by mitochondria, have been found to be elevated significantly in SLE [20, 21] . As the key regulator of energy expenditure, mTOR has been reported to control mitochondrial oxidative function in skeletal muscle cells [22] . However, whether mTOR could control the production of mitochondrial ROS in bone marrow-derived macrophages (BMDMs) remains unknown.
In this study, B6. /J mice were divided into INK128-treated and vehicle groups (n = 6 per group). Mice in the INK128-treated group were given 1 mg/kg body weight of INK128 by oral gavage from Monday to Friday every week, and mice in the vehicle group were given a solution containing 5% NMP (1-methyl-2-pyrrolidinone; Sigma), 15% PVP (polyvinylpyrrolidone K30; Sigma), and 80% ddH 2 O. These mice were given a gavage at 14 weeks of age, and they were euthanized at 24 weeks of age. The INK128 solution was prepared as previously described [23] . Briefly, PVP was dissolved in ddH 2 O at a concentration of 15.8 g/84.2 ml. INK128 was then dissolved in NMP and diluted to 5% in the PVP solution.
Generation of BMDMs
Bone marrow (BM) cells were obtained from 8-to 10-week-old female C57BL/6 mice and cultured in RPMI 1640 medium (Gibco, Grand Island, USA) containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 ng/ml M-CSF (Miltenyi Biotec, Bergisch Gladbach, Germany). The culture medium was renewed on Day 3, and BMDMs were collected and seeded in 12-well plates on Day 5.
Activation of NLRP3 inflammasome in vitro
To induce NLRP3 inflammasome activation, BMDMs were seeded at a density of 8 × 10 5 cells/well in a 12-well plate and cultured overnight. On the next day, the cells were primed with 500 ng/ml LPS, and 3 h later, the medium was changed to serum-free RPMI 1640 medium. Then, the cells were stimulated with 5 mM ATP or 5 μM nigericin for 30 min.
Western blot analysis
Cell supernatants were centrifuged at 300 g for 10 min to remove cell debris. Thereafter, 450 μl of the supernatant was concentrated using ultrafiltration devices (Merck Millipore, Bedford, USA) according to the manufacturer's instructions. Cell monolayers were directly lysed with SDS lysis buffer (Beyotime). Proteins were separated by 12% SDS-PAGE and transferred to PVDF membranes (Merck Millipore). The membranes were blocked with 5% BSA in room temperature for 2 h and incubated with primary antibodies at 4°C overnight. On the next day, protein bands were incubated with corresponding secondary antibodies. The bands were finally observed by using ECL Plus western blotting detection reagents (Merck Millipore).
ELISA
The level of IL-1β in the mouse serum or in the cell culture supernatant was detected using a commercial kit (Biolegend, San Diego, USA) according to the manufacturer's instructions. The level of IL-18 in the cell culture supernatant was examined by using IL-18 ELISA kit (eBioscience, Waltham, USA) according to the manufacturer's instructions. The proteinuria level was determined using a mouse albumin ELISA quantitation set (Bethyl Laboratories, Montgomery, USA) according to the manufacturer's instructions.
Detection of ROS
The production of ROS was evaluated using DCFH-DA (Beyotime), which can be oxidized to the fluorescent product DCF. Briefly, BMDMs were seeded at 1 × 10 4 cells/well in a 96-well plate and cultured overnight, and the culture medium (RPMI 1640 medium containing 10% FBS) was replaced by serum-free RPMI 1640 medium containing 10 μM DCFH-DA after cell stimulation. The reaction mixture was then incubated in the dark at 37°C for 20 min. The fluorescence intensity of DCF was detected using a fluorescent microplate reader (Synergy HT; Biotek, Winooski, USA) with the excitation wavelength at 488 nm and the emission wavelength at 525 nm. As previously reported [24] , mitochondrial ROS level was measured using MitoSOX Red (Sigma). Briefly, BMDMs were suspended in serum-free RPMI 1640 medium containing 2 μM MitoSOX Red and incubated in the dark at 37°C for 10 min. Subsequently, the cells were washed twice with RPMI 1640 medium, and the fluorescence intensity was examined by FACSCalibur flow cytometry analysis (BD Biosciences, Franklin Lakes, USA).
Measurement of mitochondrial complex activity
Cell mitochondria isolation kit (Genemed Scientifics, Shanghai, China) was used to isolate mitochondria from BMDMs according to the manufacturer's instructions. Subsequently, mitochondrial complex I-IV activities were detected using mitochondria respiratory chain activity assay kits (Genemed Scientifics) according to the manufacturer's instructions.
RNA extraction and quantitative real-time PCR
Total RNA was obtained by using Trizol Reagent (Invitrogen) according to the manufacturer's instructions. Real-time PCR reactions were performed with StepOne sequence detection system (Applied Biosystems, Waltham, USA) using SYBR green dye (Invitrogen). The reaction condition was 10 min at 95°C, 45 cycles of 15 s at 95°C, 30 s at 60°C, 30 s at 72°C. Relative gene expression was determined by 2 −ΔΔCT formula. GAPDH was used as an internal control. The primer sequences are listed in Table 1 .
Hematoxylin and eosin staining
INK128-treated and vehicle B6.MRL-FAS lpr /J mice were euthanized and kidney tissues were collected immediately. The kidney tissues were fixed with 4% paraformaldehyde, embedded in paraffin, cut into 4-mm-thick sections and stained with hematoxylin and eosin (HE) (Beyotime) according to the manufacturer's instructions.
Statistical analyses
Data are presented as the mean ± SEM of at least three independent experiments. ANOVA and unpaired Student's t-test were used for data analysis. P-values < 0.05 were considered statistically significant.
Results
Both mTOR and NLRP3 inflammasome are hyperactivated in B6.MRL-FAS lpr /J lupus mice A comparison of protein levels of components of the NLRP3 inflammasome pathway in kidney tissues from C57BL/6 and B6.MRL-FAS lpr /J mice revealed that IL-1β, cleaved caspase-1 and NLRP3
were highly expressed in B6.MRL-FAS lpr /J mice (Fig. 1A,B ).
Additionally, the serum level of IL-1β in B6.MRL-FAS lpr /J mice was significantly higher than that in healthy controls (Fig. 1C) . mTOR exists within two distinct protein complexes, mTORC1 and mTORC2, which have different substrate specificities [16] . We examined the activation status of mTOR in lupus mice. As shown in Fig. 1D , the phosphorylation levels of mTORC1 substrate 4E-BP1 and mTORC2 substrate AKT were increased significantly in lupus kidneys. These results indicate that the overactivation of mTOR may be associated with hyperactivation of NLRP3 inflammasome in lupus mice.
Inhibition of mTOR suppresses NLRP3 inflammasome activation through an NF-κB-independent mechanism INK128 (also known as MLN0128) is a dual mTORC1/2 inhibitor [25] . To investigate the role that mTOR plays in the activation of NLRP3 inflammasome, LPS-primed BMDMs were pretreated with different doses of INK128 and then stimulated with ATP ( Fig. 2A-C) .
As shown in Fig. 2A , the release of IL-1β and cleaved caspase-1 in the cell supernatant was inhibited by INK128 in a dose-dependent manner. Moreover, ELISA assay also revealed that INK128 suppressed the secretion of IL-1β and IL-18 in BMDMs (Fig. 2B) . As shown in (Fig. 2C) . Another typical NLRP3 inflammasome agonist, nigericin, was used to test whether INK128 only inhibits ATP-induced NLRP3 inflammasome activation. BMDMs were pretreated with or without INK128 before LPS stimulation. The cells were then left unstimulated or stimulated with ATP or nigericin. The results showed that INK128 could inhibit the processing of caspase-1 (Fig. 2D ) and the production of IL-1β and IL-18 ( Fig. 2E ) in both ATP-and nigericin-stimulated BMDMs. To examine the inhibitory effect of INK128 on mTORC1/2 signaling, BMDMs were treated with or without different doses of INK128 for 3 h. The inhibitory effect of INK128 on phosphorylation status of 4E-BP1 and AKT is shown in Fig. 2F . The sufficient expression of NLRP3 is a critical factor for NLRP3 inflammasome activation. Thus, we tested whether mTOR affects the expression of NLRP3. BMDMs were pretreated with different doses of INK128 before LPS stimulation. The real-time PCR results revealed that INK128 decreased the LPS-induced NLRP3 expression in a dose-dependent manner (Fig. 2G) . The western blot analysis results confirmed the inhibitory effect of INK128 on LPSinduced NLRP3 expression (Fig. 2H) . As the expression of NLRP3 usually engages the activation of NF-κB [7] , we then examined whether INK128 influences NF-κB signaling. BMDMs were pretreated with or without INK128, then the cells were treated with LPS for different times (0, 15, 30, and 60 min). The western blot analysis results showed that the phosphorylation status of NF-κB was not affected by INK128 (Fig. 2I) . To address whether INK128 influences the expression of other inflammasome receptors, we detected NLRP1, AIM2 and NLRC4 expression in control BMDMs and LPS-stimulated BMDMs pretreated with or without INK128. As shown in Fig. 2J , INK128 treatment had no influence on the expressions of these receptor genes, demonstrating the specific inhibitory effect of INK128 on NLRP3. Together, these data demonstrate that the inhibition of mTOR can specifically suppress NLRP3 inflammasome activation in an NF-κB-independent manner.
Furthermore, rapamycin, a typical mTORC1 inhibitor, and Torin, a selective mTORC1/2 inhibitor, were used to confirm the participation of both mTORC1 and mTORC2 in the regulation of NLRP3 inflammasome. As shown in Supplementary Fig. S1 , Torin had potent inhibitory effect on LPS/ATP-induced IL-1β and IL-18 production, which was almost equivalent to INK128. Rapamycin pretreatment also inhibited the secretion of IL-1β and IL-18 significantly but was not as potent as INK128 and Torin. These results suggest that both mTORC1 and mTORC2 are involved in controlling the NLRP3 inflammasome activation.
mTOR controls mitochondrial ROS production during NLRP3 inflammasome activation
It has been reported that the production of ROS is involved in the activation of the NLRP3 inflammasome [26] . We then examined whether mTOR could control the production of ROS in BMDMs. As shown in Fig. 3A, INK128 decreased the cellular ROS production induced by LPS/ATP in a dose-dependent manner. As mitochondria are the exact site for ROS production during NLRP3 inflammasome activation [26] , we examined the inhibitory effect of INK128 on mitochondrial ROS production. The flow cytometry results showed that the level of mitochondrial ROS generated by LPS/ATP was significantly decreased by INK128 pretreatment (Fig. 3B) . In addition, both Torin and rapamycin prominently suppressed the production of cellular ROS and mitochondrial ROS in BMDMs ( Supplementary Fig. S2 ). However, the inhibitory effect of rapamycin on ROS production was not as powerful as that of INK128 and Torin.
We also examined whether mTOR could influence the activity of mitochondrial respiratory chain complexes. As shown in Fig. 3C , The phosphorylation levels and total protein levels of the mTORC1 substrate 4E-BP1 and mTORC2 substrate AKT in the kidney tissues were examined by western blot analysis. Statistical graphs of band intensities were shown on the right of the blots. Data are expressed as the mean ± SEM and represent three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
INK128 restored the decreased mitochondrial complex I activity caused by LPS/ATP treatment, although it had little effect on mitochondrial complex II-IV. Collectively, these data suggest that mTOR is involved in mitochondrial ROS production during NLRP3 inflammasome activation.
mTOR modulates NLRP3 inflammasome activation via ROS-induced NLRP3 expression
NAC, a potent ROS scavenger, was used to examine the role of ROS in the activation of NLRP3 inflammasome. As shown in Fig. 4A ,B, BMDMs were pretreated with or without different doses of NAC before LPS stimulation, then the cells were left unstimulated or stimulated by ATP. And the result showed that LPS/ATP-induced production of cleaved caspase-1 and IL-1β was indeed inhibited by NAC in a dose-dependent manner. As inhibition of mTOR suppressed LPS-induced NLRP3 expression (Fig. 2G,H) , we investigated the effect of ROS inhibition on NLRP3 expression. NAC pretreatment significantly decreased LPS-induced NLRP3 expression (Fig. 4C,D) . Furthermore, rotenone, which induced robust mitochondrial ROS production through the inhibition of respiratory chain, partially restored the inhibitory effect of INK128 on NLRP3 expression and IL-1β secretion (Fig. 4E) . Additionally, real-time PCR results demonstrated that rotenone rescued the expression of NLRP3 partially in BMDMs treated with INK128 (Fig. 4F) . However, neither INK128 nor rotenone treatment had influence on LPS-induced IL-1β mRNA expression (Fig. 4F) (Fig. 5A) . In addition, a (H) BMDMs were pretreated with or without INK128 (30 nM) for 1 h; then, the cells were left unstimulated or stimulated with LPS (500 ng/ml) for 3 h. The protein expression of NLRP3 was examined by western blot analysis. (I) BMDMs were pretreated with or without INK128 (30 nM) for 1 h. Thereafter, the cells were treated with LPS (500 ng/ml) for the indicated time. The phosphorylation level and the total protein level of P65 and IκBα were detected by western blot analysis. (J) Relative expression of NLRP1, AIM2, and NLRC4 in control BMDMs and BMDMs pretreated with or without INK128 (30 nM) for 1 h and then stimulated with LPS (500 ng/ml) for 3 h. Data are shown as the mean ± SEM, representing three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. BMDMs were treated with or without rotenone (1 μM) for 1 h, and then, the cells were treated with or without INK128 (30 nM) for 1 h. Subsequently, LPS was added to prime the cells, and 3 h later, they were stimulated with or without ATP. Western blot analysis of IL-1β and cleaved caspase-1 in the supernatants and western blot analysis of NLRP3, pro-IL-1β and pro-caspase-1 in the lysates. (F) BMDMs were treated with or without rotenone (1 μM) for 1 h, and then, the cells were treated with or without INK128 (30 nM) for 1 h. After that, the cells were left unstimulated or stimulated with LPS (500 ng/ml) for 3 h. The relative expression of NLRP3 and IL-1β was detected by real-time PCR. Data are presented as the mean ± SEM, representing three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
pronounced decrease in the urine protein level was shown in the INK128-treated group (Fig. 5B) . Taken together, these data demonstrated that the inhibition of mTOR by INK128 markedly alleviated lupus nephritis in B6.MRL-FAS lpr /J mice.
Inhibition of mTOR blocks NLRP3 inflammasome activation in vivo
To explore the mechanisms underlying the protective effect of mTOR inhibition on B6.MRL-FAS lpr /J mice, we examined the protein levels of NLRP3 and cleaved caspase-1 in renal tissues. The western blot analysis results revealed that the protein levels of NLRP3 and cleaved caspase-1 in INK128-treated mice were significantly lower than those in vehicle-treated mice (Fig. 6A) .
Meanwhile, the decreased mRNA expression of NLRP3 was observed in the kidney tissues from INK128-treated mice (Fig. 6B) .
The ELISA results revealed a pronounced decrease in the serum level of IL-1β in INK128-treated mice compared with vehicle-treated mice (Fig. 6C) . These results verified the inhibitory effect of INK128 on NLRP3 inflammasome activation in vivo.
Discussion
The abnormal activation of the NLRP3 inflammasome has been connected to the pathogenesis of multiple inflammatory disorders, including atherosclerosis, arthritis, colonitis, and SLE [5, 28] . However, the underlying mechanisms of NLRP3 inflammasome activation in SLE are still unclear. As a key regulator of cellular metabolism, mTOR signaling controls global protein synthesis to support many cellular events, such as the production of proinflammatory cytokines IL-6, TNF-α, IL-12 and IFN-α [16, [29] [30] [31] . It was previously reported that the activity of mTORC1 is significantly increased in T cells from SLE patients [19] . Rapamycin, the mTORC1 inhibitor, could significantly alleviate lupus syndrome both in lupus-prone mice [32] and in SLE patients [33] . In the present study, we demonstrated for the first time that both mTORC1 and mTORC2 were hyperactivated in lupus mice. Blocking mTOR by INK128, a novel dual mTORC1/2 inhibitor, suppressed caspase-1 activation and the maturation of IL-1β both in vitro and in vivo, suggesting that mTOR might positively regulate NLRP3 inflammasome activation in lupus mice.
Although the NLRP3 inflammasome can sense diverse PAMPs and DAMPs, it is unlikely that the NLRP3 inflammasome interacts directly with all the activators. There must be common pathways for these stimuli to activate the NLRP3 inflammasome. Recently, the concept of ROS as critical positive regulators of NLRP3 inflammasome activation has attracted particular attention [26, 34] . ROS inhibitors were reported to block the priming of the NLRP3 inflammasome [35] . Moreover, the production of ROS has been implicated in the regulation of several LPS-induced inflammatory cytokines [36] , indicating a proinflammatory function of ROS. The persistent production of ROS has been found to be involved in the pathogenesis of SLE [37, 38] . We then tested whether mTOR has a regulatory effect on ROS production in BMDMs. Here, we reported for the first time that the inhibition of mTOR contributes to reduced ROS production in BMDMs. INK128 prominently decreased the LPS/ATP-induced production of ROS in BMDMs. Rapamycin is a classical mTORC1 inhibitor, and it was previously reported that rapamycin treatment attenuated lupus symptoms in SLE patients and lupus mice [32, 33] . In contrast to rapamycin, INK128 can inhibit both mTORC1 and mTORC2 [39] . In this study, we compared the inhibitory effect of three mTOR inhibitors (INK128, Torin, and rapamycin) on ROS production during NLRP3 inflammasome activation. We found that rapamycin could suppress ROS production in BMDMs, but the inhibitory effect of rapamycin was not as potent as that of INK128 and Torin. These results suggest that both mTORC1 and mTORC2 are involved in the regulation of ROS production during NLRP3 inflammasome activation. However, how mTOR regulates the production of ROS needs to be further studied in the future.
It has been shown that INK128 can inhibit several proinflammatory cytokines (IL-1, IL-6 and TNF-α) in LPS-activated RAW264.7 cells [40] . Although INK128 is involved in inflammatory cytokine production, it remains unclear whether INK128 could regulate NLRP3 inflammasome activation. In this study, we demonstrated that INK128 could potently suppress IL-1β and IL-18 secretion induced by NLRP3 inflammasome agonists. In addition, we found that the inhibitory effect of rapamycin on the NLRP3 inflammasome was not comparable to INK128 in BMDMs. We also demonstrated that INK128 could prevent the development of lupus nephritis in B6. MRL-FAS lpr /J mice, indicated by reduced glomerulonephritis and proteinuria in INK128-treated mice. These results suggest that INK128 may be a promising compound for the treatment of SLE. Further studies on the side effects of INK128 are needed in the future.
Conclusion
In conclusion, our results demonstrate that the inhibition of mTOR suppresses NLRP3 inflammasome activation partially via ROS-induced NLRP3 expression. This provides a novel mechanism that might contribute to abnormal activation of the NLRP3 inflammasome in lupus mice. Inhibition of mTOR by INK128 effectively alleviates lupus syndromes in B6.MRL-FAS lpr /J mice, indicating that INK128 may be a potential inhibitor for the therapeutic intervention of SLE.
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